AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01952678 — intervention group
Intervention type: OTHER
Intervention: DaTscan™ - Non-Caucasian Participants
Description: Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
Study NCT01952678 — intervention group
Intervention type: OTHER
Intervention: DaTscan™ - Caucasian Participants
Description: Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
Study NCT02636283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: Oral pills
Study NCT02636283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The placebo pills
Study NCT03309605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
Study NCT03309605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05328895 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine
Description: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Study NCT05328895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine
Description: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Study NCT00476788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Insulin Management System
Description: Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
Study NCT01010620 — intervention group
Intervention type: BEHAVIORAL
Intervention: Various Screening psychiatric and medical assessments
Description: Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
Study NCT03767010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no PLM)
Description: Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
Study NCT03767010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLM
Description: PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
Study NCT01341912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human-cl rhFVIII
Description: Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
Study NCT03679494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making support tool
Description: Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
Study NCT01210937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEA and TCD monitoring
Description: All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
Study NCT03020693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive electrostimulation combined with exercises
Description: Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
Study NCT03020693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo electrostimulation and exercises
Description: First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
Study NCT04449029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide therapy
Description: Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
Study NCT00150644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 10mg Tablet, oral Daily for 12 weeks
Study NCT00150644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
Study NCT00150644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet, oral Daily for 12 weeks
Study NCT02968589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Study NCT02968589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Study NCT01525121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory Rib Cage Compression
Description: The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
Study NCT03934697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: imaginal exposure therapy
Description: All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
Study NCT03433027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-401
Description: BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
Study NCT01693302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin
Description: The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
Study NCT02939703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
Study NCT02939703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
Study NCT04241757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ElectroCardioGram (ECG)
Description: Collection of results ElectroCardioGram (ECG).
Study NCT05713058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTRC diet
Description: 12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) focusing on the distribution of macronutrients within the day so as to avoid carbohydrate consumption after lunch
Study NCT00768469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Administered orally, continuous, once daily.
Study NCT00768469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV, on days 1, 8, 15 of 28 day cycle.
Study NCT01158898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPI ASM8
Description: ASM8 4mg/mL (low dose) daily for 14 days by inhalation
Study NCT01158898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPI ASM8
Description: ASM8 4mg/mL (high dose) daily for 14 days by inhalation
Study NCT01158898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPI ASM8
Description: Placebo PBS solution daily for 14 days by inhalation
Study NCT02846077 — intervention group
Intervention type: OTHER
Intervention: No intervention. Observation only
Description: No intervention. Observation only
Study NCT01429649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy or radiofrequency ablation
Description: Cryoablation or Radiofrequency ablation is performed under CT image guidance.
Study NCT03183635 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Balance training
Description: Improvement of balance ability in stroke patients
Study NCT03042273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Strength Cranberry
Description: Softgel capsule
Study NCT03042273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soy oil to match High Strength Cranberry Softgel Capsule
Study NCT02953158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haas Avocado
Description: Hypocaloric weight loss diet
Study NCT02953158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Dietary Counseling
Study NCT01661985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
Study NCT01661985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
Study NCT03183635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Improvement of balance ability in stroke patients
Study NCT01661985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lymecycline
Description: Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
Study NCT03868553 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: observational study
Study NCT00607750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG003 (mecamylamine)
Description: 1% Ophthalmic solution, eyedrop BID, 48 weeks
Study NCT00607750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eyedrops, BID, 48 weeks
Study NCT04562363 — intervention group
Intervention type: PROCEDURE
Intervention: Suturing of a laparotomic wound with modified methods
Description: Suturing the white line of the abdomen with the help of developed techniques aimed at preventing hernias and eventrations
Study NCT04789824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eyelid hygiene
Description: EH
Study NCT03777930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drugs
Description: According to the NCCN Guidelines
Study NCT03777930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide and megestrol acetate
Description: The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
Study NCT03777930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimal support treatment
Description: Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
Study NCT00069121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
Study NCT00069121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
Study NCT00069121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin (LV)
Description: Administered by one of two regimens, as specified in the arm description.
Study NCT00069121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: Administered by one of two regimens, as specified in the arm description.
Study NCT01208181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Description: One tablet orally once daily for 6 weeks.
Study NCT01208181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Description: One tablet orally once daily for 6 weeks.
Study NCT01208181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Etoricoxib 60 mg
Description: One tablet orally once daily for 6 weeks.
Study NCT01208181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Etoricoxib 60 mg
Description: One tablet orally once daily for 6 weeks.
Study NCT01208181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Etoricoxib 90 mg
Description: One tablet orally once daily for 6 weeks
Study NCT01208181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Etoricoxib 90 mg
Description: One tablet orally once daily for 6 weeks
Study NCT03685656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slimming gel
Description: On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
Study NCT03685656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Slimming gel placebo
Description: On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
Study NCT00495846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR, Lanreotide Autogel
Description: Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
Study NCT00495846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Locoregional treatments
Study NCT03488992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MVM/phytochemical supplement
Description: Consumption of an MVM/phytochemical supplement for 8 weeks
Study NCT03488992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
Study NCT02942498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 10mg/Kg Vitamin E 10 mg/Kg
Study NCT02942498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04942548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.
Study NCT01309126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG + cetuximab
Description: Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
Study NCT01309126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
Study NCT02490540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil SPI analgesia
Description: Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
Study NCT02490540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil ANI analgesia
Description: Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Study NCT02196909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor function and strength assessment
Study NCT02196909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NMR assessment
Study NCT02490540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil anesthesiologist analgesia
Description: Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Study NCT03008551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Each participant will receive empagliflozin 25mg daily for 3 months.
Study NCT03008551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Each participant will receive metformin 1500mg daily for 3 months.
Study NCT00227461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wait first, then levetiracetam
Description: Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
Study NCT00227461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levetiracetam first, then wait
Description: subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
Study NCT00550628 — intervention group
Intervention type: GENETIC
Intervention: DNA methylation analysis
Study NCT02196909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24h urine and serum collection
Study NCT01879852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quadriceps intensive strengthening
Description: Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
Study NCT01879852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
Study NCT00550628 — intervention group
Intervention type: GENETIC
Intervention: fluorescence in situ hybridization
Study NCT00550628 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT00550628 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Study NCT00550628 — intervention group
Intervention type: GENETIC
Intervention: protein expression analysis
Study NCT00550628 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT01879852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)